Biomarkers of Metabolic Syndrome in Clinical Trials
This will discuss the latest developments in biomarkers for metabolic syndrome. The topics will include: 1) Pre-analytical and analytical concerns regarding gut and incretin hormones, 2) dysfunctional HDL biomarkers in metabolic syndrome, and 3) kidney injury markers and their usefulness in diabetic nephropathy.
Smarter Regulation: the Key to Radical Transformation of the Pharmaceutical Industry
Joyce Tait, Professor, University of Edinburgh, speaking at the Pharma Outsourcing Congress 2010.
Legal Aspects of Outsourcing Drug Discovery
Hiroshi Sheraton, Partner, McDermott Will & Emery UK, speaking at the Pharma Outsourcing Congress 2010.
A Quality Assurance Perspective on Selecting and Monitoring Contract Research Organizations (CROs)
Thomas Ott, Pharmaceutical Consultant, speaking at the Pharma Outsourcing Congress 2010.
Education and Training in Clinical Research: What are the Best Outsourcing Strategies?
Heinrich Klech, Professor/CEO, Vienna School of Clinical Research, speaking at the Pharma Outsourcing Congress 2010.
Assessing the Security Practices of Partners
Peter Hesse, President, Gemini Security Solutions, Inc, speaking at the Pharma Outsourcing Congress 2010.
Outsourcing in Pharma R&D, Gambling or Added Value?
Michael Becker, Head of Marketing and Communication, Solvias AG, speaking at Pharma Outsourcing Congress 2010
MAPK Inhibitors: New Chemotherapeutic Opportunities for the ‘Ageing’ Disease
Mark Bagley, Reader in Organic Chemistry, Cardiff University, speaking at MedChem Europe 2009
|<< || 1 2 3 ||>>|
|Showing Results 21 - 28 of 28|